Abstract
Two large, randomized, double-blind, placebo-controlled multicenter studies, one North American and one European, examined the efficacy and safety of 300 and 600 mg/day tolcapone in similar populations of patients (n = 379) with Parkinson's disease currently taking levodopa and experiencing motor fluctuations. Change in "on-off" function was the most important end-point assessment. The two studies found similar results. The percentage of "on" time improved significantly and "off" time was reduced. Daily levodopa dosage requirements decreased significantly. The most common and significant adverse event was increased dyskinesia; hallucinations were not frequently encountered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.